Yonsei Med J.  2017 Nov;58(6):1144-1151. 10.3349/ymj.2017.58.6.1144.

Identification of 10 Candidate Biomarkers Distinguishing Tuberculous and Malignant Pleural Fluid by Proteomic Methods

• Lee CY
• Hong JY
• Lee MG
• Suh IB

• KMID: 2418896
• DOI: http://doi.org/10.3349/ymj.2017.58.6.1144

Abstract

PURPOSE
Pleural effusion, an accumulation of fluid in the pleural space, usually occurs in patients when the rate of fluid formation exceeds the rate of fluid removal. The differential diagnosis of tuberculous pleurisy and malignant pleural effusion is a difficult task in high tuberculous prevalence areas. The aim of the present study was to identify novel biomarkers for the diagnosis of pleural fluid using proteomics technology.
MATERIALS AND METHODS
We used samples from five patients with transudative pleural effusions for internal standard, five patients with tuberculous pleurisy, and the same numbers of patients having malignant effusions were enrolled in the study. We analyzed the proteins in pleural fluid from patients using a technique that combined two-dimensional liquid-phase electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry.
RESULTS
We identified a total of 10 proteins with statistical significance. Among 10 proteins, trasthyretin, haptoglobin, metastasis-associated protein 1, t-complex protein 1, and fibroblast growth factor-binding protein 1 were related with malignant pleural effusions and human ceruloplasmin, lysozyme precursor, gelsolin, clusterin C complement lysis inhibitor, and peroxirexdoxin 3 were expressed several times or more in tuberculous pleural effusions.
CONCLUSION
Highly expressed proteins in malignant pleural effusion were associated with carcinogenesis and cell growth, and proteins associated with tuberculous pleural effusion played a role in the response to inflammation and fibrosis. These findings will aid in the development of novel diagnostic tools for tuberculous pleurisy and malignant pleural effusion of lung cancer.

Keyword

Proteomics; pleural effusion; carcinoma; non-small-cell lung; tuberculosis

MeSH Terms

Adult
Aged
Aged, 80 and over
Biomarkers/*metabolism
Diagnosis, Differential
Female
Humans
Lung Neoplasms/metabolism
Male
Middle Aged
Pleural Effusion/diagnosis/*metabolism
Pleural Effusion, Malignant/*diagnosis
*Proteomics
Tuberculosis, Pleural/*diagnosis/microbiology
Biomarkers

Figure

• 

  Fig. 1 (A) 2-DE profile of tuberculous pleural effusion sample separated on a strip and then resolved on a gel. (B) 2-DE profile of malignant pleural effusion sample separated on a strip and then resolved on a gel.

• 

  Fig. 2 (A) Mass spectra of gel-excised protein of metastasis-associated protein 1. (B) Mass spectra of gel-excised protein of fibroblast growth factor-binding protein 1.

Reference

1. Egan AM, McPhillips D, Sarkar S, Breen DP. Malignant pleural effusion. QJM. 2014; 107:179–184.

2. Glaziou P, Floyd K, Raviglione M. Global burden and epidemiology of tuberculosis. Clin Chest Med. 2009; 30:621–636. vii

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.

4. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis (Seoul). 2016; 79:58–69.

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30.

6. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250:4007–4021.

7. Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984; 138:141–143.

8. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001; 1:377–396.

9. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY, et al. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics. 2003; 3:2472–2486.

10. Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics. 2002; 1:91–98.

11. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics. 2003; 3:36–44.

12. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395–409.

13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129–2139.

14. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013; 105:595–605.

15. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693–1703.

16. Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer. 2012; 1:36–42.

17. Tyan YC, Wu HY, Su WC, Chen PW, Liao PC. Proteomic analysis of human pleural effusion. Proteomics. 2005; 5:1062–1074.

18. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 2005; 5:31–38.

19. Beckman G, Eklund A, Fröhlander N, Stjernberg N. Haptoglobin groups and lung cancer. Hum Hered. 1986; 36:258–260.

20. Benkmann HG, Hanssen HP, Ovenbeck R, Goedde HW. Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered. 1987; 37:290–293.

21. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009; 27:2787–2792.

22. Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One. 2013; 8:e57401.

23. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009; 26:215–227.

24. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Yukiue H, Kaji M, et al. Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer. 2002; 35:149–154.

25. Yokota S, Yanagi H, Yura T, Kubota H. Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase. J Biol Chem. 1999; 274:37070–37078.

26. Yokota S, Yamamoto Y, Shimizu K, Momoi H, Kamikawa T, Yamaoka Y, et al. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones. 2001; 6:345–350.

27. Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, et al. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium. Int J Cancer. 2001; 92:374–381.

28. Cernat RI, Mihaescu T, Vornicu M, Vione D, Olariu RI, Arsene C. Serum trace metal and ceruloplasmin variability in individuals treated for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011; 15:1239–1245. i

29. Oikonomou N, Thanasopoulou A, Tzouvelekis A, Harokopos V, Paparountas T, Nikitopoulou I, et al. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax. 2009; 64:467–475.

30. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38:1543–1552.